Trial of TG4023 Combined With Flucytosine in Liver Tumors

"1. TG4023: single IT injection; possibility to re-administer once,~ * Percutaneous IT injections, under radiological or ultrasound imaging guidance~ * Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),~ * MTD injected to up to 3 different lesions (Cohort #4)~2. 5-FC (5-fluorocytosine)/flucytosine~ * Dose and dosing schedule:~ * Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L~ * Duration: 2 weeks.~ * Possible routes of administration:~ * PO: 500 mg tablets, qid~ * IV: 1% 250 mL vials, 45-minute infusions."